Dr. Wendy Fantl’s lab studies two key questions with unmet clinical need related to drug resistance and immunotherapy focusing on ovarian and kidney cancers. The lab applies multi-parametric single-cell proteomic technologies (mass cytometry aka Cytometry by Time-Of-Flight (CyTOF) and multiplex imaging (CO-Detection by indEXing (CODEX)) combined with specialized computational approaches to address these questions. These technologies reveal cell heterogeneity identifying minority cell subpopulations of interest, such as those with roles in metastasis and therapeutic resistance, that would elude bulk analyses. Dr Fantl is deeply committed to translating her findings in the lab to helping patients.